Join
Live feed
·
PRReleasevia Quantisnow
AstraZeneca PLC logo

TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

ByQuantisnow·Wall Street's wire, on your screen.
AZN· AstraZeneca PLC
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AZN (AstraZeneca PLC) and more on Quantisnow.